Multiple signaling states of G-protein-coupled receptors

Pharmacological Reviews

Volumn 57, Issue 2, 2005, Pages 147-161

  Perez, Dianne M ^a   Karnik, Sadashiva S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,3 DIHYDRO 2 PENTYLBENZOFURAN 2 YL) 2 IMIDAZOLINE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; EISAI 1; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; ISOPRENALINE; METHADONE; MORPHICEPTIN[3 (N METHYLPHENYLALANINE) 4 DEXTRO PROLINAMIDE]; MORPHINE; MU OPIATE RECEPTOR AGONIST; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NEUROMEDIN N; NEUROTENSIN RECEPTOR 1 AGONIST; NORADRENALIN; PROTEIN KINASE C INHIBITOR; SR 1211463B; SR 121463B; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V2 RECEPTOR;

CALCIUM MOBILIZATION; CELL LINE; CELL STRAIN 3T3; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CHIMERA; CHINESE HAMSTER; CHO CELL; CHROMATOPHORE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DESENSITIZATION; DISULFIDE BOND; DRUG EFFICACY; DRUG POTENCY; INTERNALIZATION; KINETICS; NONHUMAN; PALMITOYLATION; PHOSPHORYLATION; PHOTOLYSIS; PRIORITY JOURNAL; RETINITIS PIGMENTOSA; REVIEW; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS;

ANIMALS; HUMANS; MODELS, MOLECULAR; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; RHODOPSIN; SIGNAL TRANSDUCTION;

EID: 22944487986     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.57.2.2     Document Type: Review

References (99)

1. Altenbach C, Farrens DL, Khorana HG, and Hubbell WL (1996) Structural features and light dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: a site-directed spin labeling study. Biochemistry 35:12470-12478.
2. Applebury ML and Hargrave PA (1986) Molecular biology of the visual pigments. Vision Res 26:1881-1895.
3. Arden JR, Segredo V, Wang Z, Lameh J, and Sadee W (1995) Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged μ-opioid receptor expressed in HEK 293 cells. J Neurochem 65:1636-1645.
4. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
5. 1-adrenoceptor. Mol Pharmacol 63:1312-1321.
6. Barak LS, Oakley RH, Laporte SA, and Caron MG (2001) Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98:93-98.
7. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
8. Bertin B, Freissmuth M, Jockers R, Strosberg AD, and Marullo S (1994) Cellular signaling by an agonist-activated receptor/Gs alpha fusion protein. Proc Natl Acad Sci USA 91:8827-8831.
9. Blake AD, Bot G, Freeman JC, and Reisine T (1997) Differential opioid agonist regulation of the mouse μ-opioid receptor. J Biol Chem 272:782-790.
10. Bockaert J, Marin P, Dumuis A, and Fagni L (2003) The 'magic tail' of G protein-coupled receptors: an anchorage for functional protein networks. FEBS Lett 546:65-72.
11. 2-adrenoceptor. Nature (Lond) 374:272-276.
12. Carter PH, Petroni BD, Gensure RC, Schipani E, Potts JT Jr, and Gardella TJ (2001) Selective and nonselective inverse agonists for constitutively active type-1 parathyroid hormone receptors: evidence for altered receptor conformations. Endocrinology 142:1534-1545.
13. Chaipatikul V, Loh HH, and Law PY (2003) Ligand-selective activation of μ-opioid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain. J Pharmacol Exp Ther 305:909-918.
14. Chakrabarti S, Law PY, and Loh HH (1998) Distinct differences between morphine- and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin-μ-opioid receptor complexes demonstrated by cyclic AMP-dependent protein kinase phosphorylation. J Neurochem 71:231-239.
15. Chen G, Jayawickreme C, Way J, Armour S, Queen K, Watson C, Ignar D, Chen WJ, and Kenakin T (1999) Constitutive receptor systems for drug discovery. J Pharmacol Toxicol Methods 42:199-206.
16. Chen G, Way J, Armour S, Watson C, Queen K, Jayawickreme CK, Chen WJ, and Kenakin T (2000) Use of constitutive G protein-coupled receptor activity for drug discovery. Mol Pharmacol 57:125-134.
17. Chidiac P, Hebert TE, Valiquette M, Dennis M, and Bouvier M (1994) Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499.
18. 2-adrenergic receptor. Mol Pharmacol 50:662-669.
19. Clark AJ (1937) General pharmacology, in Handbook of Experimental Pharmacology, vol 35, 625 p, Springer Verlag, Berlin, Germany.
20. Delaney JK, Schweiger U, and Subramaniam S (1995) Molecular mechanism of protein-retinal coupling in bacteriorhodopsin. Proc Natl Acad Sci USA 92:11120-11124.
21. DeLean A, Stadel JM, and Lefkowitz RJ (1980) A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J Biol Chem 255:7108-7117.
22. Farahbakhsh ZT, Ridge KD, Khorana HG, and Hubbell WL (1995) Mapping light-dependent structural changes in the cytoplasmic loop connecting helices C and D in rhodopsin: a site-directed spin labeling study. Biochemistry 34:8812-8819.
23. Farrens DL, Altenbach C, Yang K, Hubbell WL, and Khorana HG (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (Wash DC) 274:768-770.
24. Filipek S, Stenkamp RE, Teller DC, and Palczewski K (2003) G protein-coupled receptor rhodopsin: a prospectus. Annu Rev Physiol 65:851-879.
25. Ganguli SC, Park CG, Holtmann MH, Hadac EM, Kenakin TP, and Miller LJ (1998) Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. J Pharmacol Exp Ther 286:593-598.
26. o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138:775-786.
27. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin J-S, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, et al. (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100:11086-11091.
28. 2 adrenoceptor. EMBO (Eur Mol Biol Organ) J 16:6737-6747.
29. 2-adrenergic receptor: evidence for ligand-specific conformational changes. J Biol Chem 270:28268-28275.
30. 2- adrenergic receptor. J Biol Chem 276:24433-24436.
31. Han M, Lin SW, Minkova M, Smith SO, and Sakmar TP (1996) Functional interaction of transmembrane helices 3 and 6 in rhodopsin. J Biol Chem 271:32337-32342.
32. Han M, Lou J, Nakanishi K, Sakmar TP, and Smith SO (1997) Partial agonist activity of 11-cis-retinal in rhodopsin mutants. J Biol Chem 272:23081-23085.
33. Hargrave PA, McDowell JH, Curtis DR, Wang JK, Jusczak E, Fong SL, Rao MJK, and Argos P (1997) The structure of bovine rhodopsin. Biophys Struct Mech 9:235-244.
34. Hawtin SR, Tobin AB, Patel S, and Wheatley M (2001) Palmitoylation of the vasopressin V1a receptor reveals different conformational requirements for signaling, agonist-induced receptor phosphorylation and sequestration. J Biol Chem 276:38139-38146.
35. Henderson R and Unwin PN (1975) Three-dimensional model of purple membrane obtained by electron microscopy. Nature (Lond) 257:28-32.
36. Holst B, Hastrup H, Raffetseder U, Martini L, and Schwartz TW (2001) Two active molecular phenotypes of the tachykinin NK1 receptor revealed by G-protein fusions and mutagenesis. J Biol Chem 276:19793-19799.
37. Hosohata Y, Varga EV, Stropova D, Li X, Knapp RJ, Hruby VJ, Rice KC, Nagase H, Roeske WR, and Yamamura HI (2001) Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation. Life Sci 68:2233-2242.
38. Hubbell WL, Altenbach C, Hubbell CM, and Khorana HG (2003) Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity and disulfide cross-linking. Adv Protein Chem 63:243-290.
39. Hwa J, Garriga P, Liu X, and Khorana HG (1997) Structure and function in rhodopsin: packing of the helices in the transmembrane domain and folding to a tertiary structure in the intradiscal domain are coupled. Proc Natl Acad Sci USA 94:10571-10576.
40. Hwa J, Klein-Seetharaman J, and Khorana HG (2001) Structure and function in rhodopsin: mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants. Proc Natl Acad Sci USA 98:4872-4876.
41. Ishii I, Izumi T, Tsukamoto H, Umeyama H, Ui M, and Shimizu T (1997) Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants. J Biol Chem 272:7846-7854.
42. 2A-adrenoceptors. Mol Pharmacol 53:963-968.
43. 2- adrenoceptor. Br J Pharmacol 123:701-711.
44. 2-adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J Biol Chem 272:18546-18549.
45. 2-adrenergic receptor mapped by site-selective fluorescent labeling. J Biol Chem 276:9279-9290.
46. Karnik SS and Khorana HG (1990) Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 117. J Biol Chem 265:17520-17524.
47. Karnik SS, Sakmar TP, Chen HB, and Khorana HG (1988) Cysteine residues 110 and 187 are essential for the formation of correct structure in bovine rhodopsin. Proc Natl Acad Sci USA 85:8459-8463.
48. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
49. Kenakin T (1997) Protean agonists. Keys to receptor active states? Ann NY Acad Sci 812:116-125.
50. 2-adrenergic receptor-Gs complex: evidence for agonist-specific states. Mol Pharmacol 52:144-154.
51. 2A-adrenoceptor responses in HEL 92.1.7 cells. Br J Pharmacol 132:1477-1484.
52. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237.
53. Leff P, Scaramellini C, Law C, and McKechnie K (1997) A three-state receptor model of agonist action. Trends Pharmacol Sci 18:355-362.
54. Mack M, Luckow B, Nelson PJ, Cihak J, Simmons G, Clapham PR, Signoret N, Marsh M, Stangassinger M, Borlat F, et al. (1998) Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity. J Exp Med 187:1215-1224.
55. Marie J, Koch C, Pruneau D, Paquet JL, Groblewski T, Larguier R, Lombard C, Deslauriers B, Maigret B, and Bonnafous JC (1999) Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI. Mol Pharmacol 55:92-101.
56. Menon ST, Han M, and Sakmar TP (2001) Rhodopsin: structural basis of molecular physiology. Physiol Rev 81:1659-1688.
57. Monczor F, Fernandez N, Bibiana LL, Riveiro ME, Baldi A, Shayo C, and Davio C (2003) Tiotidine, a histamine H2 receptor inverse agonist that binds with high affinity to an inactive G-protein-coupled form of the receptor. Experimental support for the cubic ternary complex model. Mol Pharmacol 64:512-520.
58. Negishi M, Irie A, Sugimoto Y, Namba T, and Ichikawa A (1995) Selective coupling of prostaglandin E receptor EP3D to Gi and Gs through interaction of alpha-carboxylic acid of agonist and arginine residue of seventh transmembrane domain. J Biol Chem 270:16122-16127.
59. i3 activation: conformational selection by high-efficacy agonists and relationship to trafficking of receptor signaling. Mol Pharmacol 62:590-601.
60. 1 angiotensin receptor is generated by angiotensin II induction. Biochemistry 35:16435-16442.
61. Palanche T, Ilien B, Zoffmann S, Reck MP, Bucher B, Edelstein SJ, and Galzi JL (2001) The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J Biol Chem 276:34853-34861.
62. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, et al. (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science (Wash DC) 289:739-745.
63. Pantaloni C, Brabet P, Bilanges B, Dumuis A, Houssami S, Spengler D, Bockaert J, and Journot L (1996) Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem 271:22146-22151.
64. Parnot C, Bardin S, Miserey-Lenkei S, Guedin D, Corvol P, and Clauser E (2000) Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay. Proc Natl Acad Sci USA 97:7615-7620.
65. 2A-adrenoceptors by co-expression with different Gα protein subunits. Neuropharmacology 42:855-863.
66. 1D-adrenergic receptors to multiple signaling pathways is both G-protein and cell-type specific. Mol Pharmacol 44:784-795.
67. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, and Graham RM (1996) Constitutive activation of a single effector pathway: evidence for multiple activation states of a G-protein-coupled receptor. Mol Pharmacol 49:112-122.
68. Pineyro G, Azzi M, De Lean A, Schiller P, and Bouvier M (2001) Short-term inverse-agonist treatment induces reciprocal changes in δ-opioid agonist and inverse-agonist binding capacity. Mol Pharmacol 60:816-827.
69. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lubsen J, Lutiger B, Metra M, Remme WJ, et al. (2003) Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 362:7-13.
70. Rao VR and Oprian DD (1996) Activating mutations of rhodopsin and other G protein-coupled receptors. Annu Rev Biophys Biomol Struct 25:287-314.
71. 2 adrenergic receptor: constitutive activation, structural instability and conformational rearrangement of transmembrane segment 6. Mol Pharmacol 56:175-184.
72. Robb S, Cheek TR, Hannan FL, Hall LM, Midgley JM, and Evans PD (1994) Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems. EMBO (Eur Mol Biol Organ) J 13:1325-1330.
73. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D, and Miller LJ (1997) Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51:357-362.
74. Ruffolo RR, Turowski BS, and Patil PN (1977) Lack of cross- desensitization between structurally dissimilar α-adrenoceptor agonists. J Pharm Pharmacol 29:378-380.
75. Sakmar TP (2002) Structure of rhodopsin and the superfamily of seven-helical receptors: the same and not the same. Curr Opin Cell Biol 14:189-195.
76. Salamon Z, Hruby VJ, Tollin G, and Cowell S (2002) Binding of agonists, antagonists and inverse agonists to the human δ-opioid receptor produces distinctly different conformational states distinguishable by plasmon-waveguide resonance spectroscopy. J Pept Res 60:322-328.
77. 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636.
78. Schertler GF and Hargrave PA (1995) Projection structure of frog rhodopsin in two crystal forms Proc Natl Acad Sci 92:11578-11582.
79. 2-adrenergic receptor/G(s) interactions: evidence for multiple receptor conformations. Mol Pharmacol 56:348-358.
80. Seifert R, Wenzel-Seifert K, Gether U, and Kobilka BK (2001) Functional differences between full and partial agonists: evidence for ligand-specific receptor conformations. J Pharmacol Exp Ther 297:1218-1226.
81. Skrzydelski D, Lhiaubet AM, Lebeau A, Forgez P, Yamada M, Hermans E, Rostene W, and Pelaprat D (2003) Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 64:421-429.
82. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond) 365:170-175.
83. Stanasila L, Lim WK, Neubig RR, and Pattus F (2000) Coupling efficacy and selectivity of the human μ-opioid receptor expressed as receptor-Gα fusion proteins in Escherichia coli. J Neurochem 75:1190-1199.
84. 2-adrenoceptor that blocks coupling to potassium but not calcium currents. Science (Wash DC) 257:977-980.
85. 2 adrenoceptor: kinetic evidence for intermediate conformational states. J Biol Chem 279:686-691.
86. Thomas WG, Qian H, Chang CS, and Karnik S (2000) Agonist-induced phosphorylation of the angiotensin II (AT1A) receptor requires generation of a conformation that is distinct from the inositol phosphate-signaling state. J Biol Chem 275:2893-2900.
87. 2 nucleotide receptors by ATP and UTP. Mol Cell Biol 206:75-89.
88. Vilardaga JP, Frank M, Krasel C, Dees C, Nissenson RA, and Lohse MJ (2001) Differential conformational requirements for activation of G proteins and the regulatory proteins arrestin and G protein-coupled receptor kinase in the G protein-coupled receptor for parathyroid hormone (PTH)/PTH-related protein. J Biol Chem 276:33435-33443.
89. Ward SD, Hamdan FF, Bloodworth LM, and Wess J (2002) Conformational changes that occur during M3 muscarinic acetylcholine receptor activation probed by the use of an in situ disulfide cross-linking strategy. J Biol Chem 277:2247-2257.
90. Watson C, Chen G, Irving P, Way J, Chen WJ, and Kenakin T (2000) The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58:1230-1238.
91. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996a) The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 178:151-167.
92. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996b) The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity. J Theor Biol 178:169-182.
93. Weiss JM, Morgan PH, Lutz MW, and Kenakin TP (1996c) The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol 181:381-397.
94. Whistler JL, Chuang HH, Chu P, Jan LY, and von Zastrow M (1999) Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23:737-746.
95. Whistler JL, Gerber BO, Meng EC, Baranski TJ, von Zastrow M, and Bourne HR (2002) Constitutive activation and endocytosis of the complement factor 5a receptor: evidence for multiple activated conformations of a G protein-coupled receptor. Traffic 3:866-877.
96. Yan EC, Kazmi MA, Ganim Z, Hou JM, Pan D, Chang BS, Sakmar TP, and Mathies RA (2003) Retinal counterion switch in the photoactivation of the G protein-coupled receptor rhodopsin. Proc Natl Acad Sci USA 100:9262-9270.
97. Zhang L, Yu Y, Mackin S, Weight FF, Uhl GR, and Wang JB (1996) Differential μ opiate receptor phosphorylation and desensitization induced by agonists and phorbol ester. J Biol Chem 271:11449-11454.
98. Zhang WB, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, and Peiper SC (2002) A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277:24515-24521.
99. 2-adrenergic receptor. J Biol Chem 273:3401-3407.